Riskpilot← Back to searchSign inGet full accessVårda Stockholm AB
ABActiveOrg 5567893390Viktoriagatan 26 AMedical specialists activities · NACE 8622Est. 20090 employees
Revenue 2024
SEK 2M
+39% vs 2023
EBITDA margin
30.5%
+18% vs 2023
Equity ratio
83.5%
Financial strength
Net profit 2024
SEK 70K
-97% vs 2023
| Revenue | SEK 2M | +39% |
| EBITDA | SEK 609K | +18% |
| Net profit | SEK 70K | -97% |
| Total assets | SEK 2,8M | -12% |
| Equity | SEK 2,4M | +3% |
| Employees | 0 | — |
Legal name
Vårda Stockholm AB
Org number
5567893390
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
21 september 2009
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas ensam av Remanius, Nils Hans
Company purpose
Bolagets verksamhet skall vara att utöra ögonoperationer, optisk rådgivning samt att idka därmed sammanhängande verksamhet.
Address
Viktoriagatan 26 A
Email
hans@remaniusvision.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 1 434 | 1 996 |
| Staff expenses | — | — | — | −401 | −541 |
| EBITDA | −2 | −1 | −1 | 516 | 609 |
| Depreciation & amort. | −0 | −0 | — | −138 | −415 |
| EBIT | −2 | −1 | −1 | 377 | 194 |
| Net financials | — | — | −6 | 1 875 | −0 |
| Profit before tax | −2 | −1 | −7 | 2 252 | 194 |
| Tax | −0 | −0 | — | −51 | −124 |
| Net profit | −2 | −1 | −7 | 2 201 | 70 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 103 | 103 | 961 | 3 229 | 2 841 |
| Equity | 88 | 88 | 100 | 2 302 | 2 371 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 15 | 15 | 860 | 928 | 469 |
| Total debt | 15 | 15 | 860 | 928 | 469 |
EBITDA margin
30.5%
This company
15.8%
Market median
+93% vs market
20202024
Equity ratio
83.5%
This company
38.2%
Market median
+119% vs market
20202024
Return on equity
2.9%
This company
18.4%
Market median
-84% vs market
20202024
Net profit margin
3.5%
This company
8.1%
Market median
-57% vs market
20202024
Asset turnover
0.70×
This company
1.12×
Market median
-38% vs market
20202024
Debt / equity
0.20×
This company
0.62×
Market median
+68% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
CY Deputy Chief Executive Officer | Deputy Chief Executive Officer | 2023 |
| Former (1) | ||
LG Audit | Audit | 2020 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2020 | |
| Deputy Board Member | 2020 | |
| Former (1) | ||
| Board of Directors | 2020 – 2023 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Vårda Stockholm AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Leif Gunnar Bohman | Audit | 0 companies |
| Changrong Yu | Deputy Chief Executive Officer | 0 companies |
| Nils Hans Remanius | Chairman | 0 companies |
| Julian David Hannes Remanius | Deputy Board Member | 0 companies |
| Rolf Magnus Wictorinsson | Board of Directors | 0 companies |